Group 1 - CITIC Construction Investment expects a net profit of 4.43 billion to 4.57 billion yuan for the first half of 2025, representing a year-on-year increase of 55%-60% [1] - New Hope anticipates a net profit of 680 million to 780 million yuan for the first half of 2025, recovering from a loss of 1.217 billion yuan in the same period last year [2] - Foton Motor forecasts a net profit of approximately 777 million yuan for the first half of 2025, marking an increase of about 87.5% year-on-year [7] Group 2 - North New Road and Bridge expects a net loss of 70 million to 85 million yuan for the first half of 2025 [2] - Nanwei Co. anticipates a net loss of 12 million to 16 million yuan for the first half of 2025 [3] - Hanhua Technology projects a net loss of 45 million to 60 million yuan for the first half of 2025, widening the loss by 11.42%-18.10% compared to the previous year [6] Group 3 - Songlin Technology expects a net profit of 90 million to 95 million yuan for the first half of 2025, a decrease of 57.06%-59.32% year-on-year [4] - Fuchun Environmental Protection anticipates a net profit of 178 million to 207 million yuan for the first half of 2025, representing a year-on-year increase of 80%-110% [18] - Ansteel Group forecasts a net loss of 1.144 billion yuan for the first half of 2025, a reduction in loss of approximately 57.46% compared to the previous year [20][22] Group 4 - China Wuyi expects a net loss of 80 million to 104 million yuan for the first half of 2025, a significant decline compared to the previous year [28] - Meikailong anticipates a net loss of 1.59 billion to 1.92 billion yuan for the first half of 2025 [26] - Aijian Group projects a net profit of 140 million yuan for the first half of 2025, a decrease of 33.26% year-on-year [27]

Core Viewpoint - The company has entered into a strategic partnership with Hangzhou Bozhi Rui Biopharmaceutical Co., Ltd. to acquire the rights to the project of Pertuzumab injection and has been granted the distribution rights of Trastuzumab injection (brand name: Anruize) in China [1] Summary by Relevant Sections - **Strategic Partnership** The company has established a strategic cooperation with Hangzhou Bozhi Rui Biopharmaceutical Co., Ltd. to obtain the project rights for Pertuzumab injection [1] - **Product Rights and Distribution** The company has been granted the distribution rights for Trastuzumab injection (Anruize) in China, which officially commenced nationwide sales in July 2025 [1] - **Regulatory Progress** The application for the marketing authorization of Pertuzumab injection was accepted by the National Medical Products Administration in October 2024, and the review and approval process is currently underway [1] - **Financial Commitment** The company has made the first payment to Bozhi Rui Biopharmaceutical for the project rights of Pertuzumab injection [1]